[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650393":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":40,"centralContacts":45,"locations":54,"responsibleParty":88,"collaborators":91,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":12,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":12,"enrollmentInfo":103,"targetDuration":12,"studyType":106,"phases":107,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":119,"whyStopped":12,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"The Jerzy Kukuczka Academy of Physical Education in Katowice","OTHER",[8,13,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Therapy in Control Group","NO_INTERVENTION","In all control groups, for ethical reasons, a standard therapy based on the principles of best clinical practice will be conducted.\n\nThere will be 3 control groups:\n\n1. patients suffering from schizophrenia control group, N = 20, standard therapy based on the principles of best clinical practices will be conducted for 12 weeks.\n2. patients suffering from schizophrenia control group requiring permanent institutional care, N = 20, standard therapy based on the principles of best clinical practices will be conducted for 12 weeks.\n3. patients (women) treated for alcohol addiction, N = 30, standard therapy based on the principles of best clinical practices will be conducted for 6 weeks.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"adults suffering from schizophrenia requiring permanent institutional care","EXPERIMENTAL","Adults suffering from schizophrenia requiring permanent institutional care, N= 20 Snoezelen® therapy will be conducted twice a week (for 30 minutes) for 12 weeks.\n\nThe goal of the therapy will be to improve cognitive functioning, organization in daily activities, mood, including reducing emotions such as anxiety and sadness, and to increase the patient's overall quality of life.",[18],"Other: Snoezelen® therapy for 12 weeks",{"label":20,"type":15,"description":21,"interventionNames":22},"Adults suffering from schizophrenia","Adults suffering from schizophrenia, N= 20 Snoezelen® therapy will be conducted twice a week (for 30 minutes) for 12 weeks.\n\nThe goal of the therapy will be to improve cognitive functioning, organization of daily activities, mood improvement, including reducing emotions such as anxiety and sadness, as well as increasing the patient's overall quality of life and emotional intelligence.",[18],{"label":24,"type":15,"description":25,"interventionNames":26},"patients (women) treated for alcohol addiction","Patients (women) treated for alcohol addiction, N= 30. Snoezelen ® therapy will be used twice a week (for 30 minutes) for 6 weeks. Then, 4 weeks after the end of therapy (so-called follow-up ), a telephone interview will be conducted to assess mood and the short Penn Alcohol Craving Scale.\n\nThe goal of the therapy will be to improve cognitive functioning, organization of daily activities, mood improvement, including reducing emotions such as anxiety and sadness, as well as increasing the patient's overall quality of life and emotional intelligence.",[27],"Other: Snoezelen® therapy for 6 weeks",[29,35],{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Snoezelen® therapy for 6 weeks","The each session of Snoezelen® therapy will last 30 minutes and will include:\n\n1. preparation and adjustment of stimuli based on information regarding the assessment of the patient's condition and problems,\n2. careful observation and appropriate care of the patient,\n3. grading of stimuli and their appropriate stimulation,\n4. experiencing therapeutic activities together with the patient,\n5. recording the therapist's presence and comments on the therapy card.",[24],[34],"Snoezelen®",{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Snoezelen® therapy for 12 weeks","Description: The each session of Snoezelen® therapy will last 30 minutes and will include: a) preparation and adjustment of stimuli based on information regarding the assessment of the patient's condition and problems, b) careful observation and appropriate care of the patient, c) grading of stimuli and their appropriate stimulation, d) experiencing therapeutic activities together with the patient, e) recording the therapist's presence and comments on the therapy card.",[20,14],[34],[41],{"name":42,"affiliation":43,"role":44},"Laura Piejko, PT, PhD","The Jerzy Kukuczka Academy of Physical Education, Katowice, Poland","PRINCIPAL_INVESTIGATOR",[46,51],{"name":47,"role":48,"phone":49,"phoneExt":12,"email":50},"Alicja Kosmalska, MD","CONTACT","032 43 28 217","alicja.kosmalska@psychiatria.com",{"name":42,"role":48,"phone":52,"phoneExt":12,"email":53},"032 43 28 185","laura.piejko@psychiatria.com",[55,73],{"facility":56,"status":12,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Jerzy Kukuczka Academy of Physical Education in Katowice, Poland","Katowice","Silesian Voivodeship","40-065","Poland","PL",{"type":63,"coordinates":64},"Point",[65,66],19.02173,50.2597,{"lat":66,"lon":65},[69,72],{"name":42,"role":48,"phone":70,"phoneExt":12,"email":71},"32 207 51 10","l.piejko@awf.katowice.pl",{"name":42,"role":44,"phone":12,"phoneExt":12,"email":12},{"facility":74,"status":12,"city":75,"state":58,"zip":76,"country":60,"countryCode":61,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Clinical Psychiatric Hospital SPZOZ in Rybnik, Poland","Rybnik","44-200",{"type":63,"coordinates":78},[79,80],18.54179,50.09713,{"lat":80,"lon":79},[83,84,85,86],{"name":47,"role":48,"phone":49,"phoneExt":12,"email":50},{"name":42,"role":48,"phone":52,"phoneExt":12,"email":53},{"name":47,"role":44,"phone":12,"phoneExt":12,"email":12},{"name":87,"role":44,"phone":12,"phoneExt":12,"email":12},"Laura Piejko, PhD",{"type":44,"investigatorFullName":89,"investigatorTitle":90,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Laura Piejko","PT, PhD. Head of Clinical Unit of Physiotherapy in Psychiatry, Department of Clinical Physiotherapy at The Jerzy Kukuczka Academy of Physical Education in Katowice, Poland",[92],{"name":74,"class":93},"UNKNOWN","100650393","snoezelen-therapy-in-adults-with-alcohol-dependence-and-adults-with-schizophrenia-100650393",false,"NCT07748078","Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia","Impact of Snoezelen Therapy in Adults With Alcohol Dependence and Adults With Schizophrenia","1. Adults suffering from schizophrenia requiring permanent institutional care, N=40\n\n   Inclusion criteria:\n   * women and men aged ≥ 18 years,\n   * consent of the patient or legal guardian to participate in the study,\n   * schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms,\n   * stable drug therapy (treatment unchanged for at least 3 months)\n   * ability to understand and follow the therapist's instructions,\n   * functional ability of everyday life on the Barthel scale below 40 points,\n\n   Exclusion criteria:\n   * lack of consent to participate in the study;\n   * pregnancy;\n   * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);\n   * unstable or untreated epilepsy, based on EEG;\n   * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);\n   * active cancer disease;\n   * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli;\n   * diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.\n2. Adults (men) suffering from schizophrenia, N=40\n\n   Inclusion criteria:\n   * men aged ≥ 18 years,\n   * consent of the patient or legal guardian to participate in the study,\n   * clinically confirmed schizophrenia with predominance of negative symptoms,\n   * stable drug therapy (treatment unchanged for at least 1 month),\n   * ability to understand and follow the therapist's instructions,\n   * functional ability of everyday life on the Barthel scale above 40 points,\n\n   Exclusion criteria:\n   * lack of consent to participate in the study;\n   * general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);\n   * unstable or untreated epilepsy, based on EEG;\n   * exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);\n   * active cancer disease;\n   * diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system disturbing body balance and limb mobility.\n3. Adults (women) addicted to alcohol, N= 60\n\nInclusion criteria:\n\n* female gender;\n* age ≥ 18 years;\n* consent of the patient or legal guardian to participate in the study;\n* alcohol dependence syndrome (F10.2 according to ICD-10);\n* history of depressive and anxiety symptoms;\n* ability to understand and follow the therapist's instructions;\n* functional ability of everyday life on the Barthel scale above 40 points.\n\nExclusion criteria:\n\n* lack of consent to participate in the study;\n* pregnancy;\n* psychoactive substances other than alcohol;\n* exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);\n* mental illnesses other than depression and anxiety disorders;\n* psychotic diseases (F20- schizophrenia and other schizophrenic disorders);\n* general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);\n* unstable or untreated epilepsy, based on EEG;\n* active cancer disease;\n* diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli;\n* severe cognitive impairment;\n* diagnosis of autism and ADHD;\n* PTSD;\n* intellectual disability (diagnosis F70 - F79);\n* diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.","ALL","18 Years",{"count":104,"type":105},140,"ESTIMATED","INTERVENTIONAL",[108],"NA","The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol.\n\nThe main questions it aims to answer are:\n\nDoes Snoezelen therapy improve the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol?\n\nThe participant will participate in Snoezelen® therapy for 6 or 12 weeks, 2 times a week (30 minutes each session).",[111,112,113],"SCHIZOPHRENIA 1 (Disorder)","Alcohol Use Disorder","Alcohol Dependence (Primary Condition)",[115,116,117,118],"Snoezelen® therapy","Snoezelen","alcohol dependence","schizophrenia","NOT_YET_RECRUITING","2026-07-31",{"date":122,"type":123},"2026-08-05","ACTUAL",{"date":125,"type":105},"2026-09-01",{"date":127,"type":105},"2027-12-30",{"name":5,"class":6},2]